Spero Therapeutics Inc (SPRO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.21-0.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Return to positive EPS: EPS -0.16 vs 0.67.
Spero got FDA approval for an oral antibiotic in June 2026. Analysts expect revenue to grow about 53% next year. The stock trades cheap with a PE of 8.9 versus peers at 21.7. This approval could start sales and improve results.
Commercial problems may slow the new drug's sales growth. The company lost money last year and faces risks. Analysts expect a loss this year before profits return. The stock has fallen 26.5% from its high.
The price is about 44% below our fair value near $4. Analysts expect 53% revenue growth next year. Our view agrees this growth is possible but risks remain.
Breaks if: Significant commercial friction reported that limits sales
Breaks if: EPS remains negative in FY27
Breaks if: YoY revenue growth falls below 30% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The company is navigating early-stage clinical developments while managing cash flow, making it a high-risk, high-reward scenario.
The current valuation suggests that the market views SPRO as cheap compared to its peers, with a notable expectations gap. However, the fragility in earnings quality indicates that the market is not fully confident in the company's execution.
Management has shown strong recent financial performance and is focused on maintaining a cash runway into 2029. However, the company's earnings quality is fragile, and near-term risks remain elevated due to the potential for guidance cuts.
The future performance of SPRO hinges on the outcomes of its ongoing clinical programs and the overall health of the healthcare sector. Key factors include the performance of sector leaders and macroeconomic indicators like employment data.
In the next 1 to 3 years, SPRO's trajectory will depend on its ability to advance its clinical programs and navigate market challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Confidence changed from 'medium' to 'high'.
Yes, our read has strengthened. The company maintained its cash runway into 2029. It also received FDA approval for Utebzi, supporting its commercialization plans. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.